Emergence of t(3;21)(q26.2;q22) during eltrombopag treatment in a patient with relapsed aplastic anemia who received chemotherapy for angioimmunoblastic T-cell lymphoma. (2022)

• Record Type: Journal Article
• Authors: Nakamura, Fumi; Nakamura, Yuka; Nannya, Yasuhito; Arai, Honoka; Shimbo, Kei; Nakamura, Yuko; Seo, Sachiko; Sasaki, Ko; Ichikawa, Motoshi; Ogawa, Seishi; Mitani, Kinuko
• Is Part Of: Leukemia research reports. Volume 17(2022)
• Publication Date: 2022
• Subjects: Eltrombopag -- Aplastic anemia -- Myelodysplastic syndromes -- Angioimmunoblastic t-cell lymphoma -- 3q26 abnormalities; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2022.100305
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: A 65-year-old man with nonsevere aplastic anemia received rabbit anti-thymocyte globulin and cyclosporine and partially responded. Six months after the initiation of treatment, he was diagnosed with stage IV angioimmunoblastic T-cell lymphoma and received chemotherapy. PET/CT scan analysis indicated a complete response. However, he showed sustained myelosuppression and was diagnosed with relapse of aplastic anemia. He did not respond to cyclosporine, eltrombopag or methenolone. Fifteen months after eltrombopag administration, he developed MDS with t(3;21)(q26.2;q22). Patients should be monitored carefully for the emergence of not only -7/del(7q) but also 3q26 abnormalities, including t(3;21)(q26.2;q22), during and after eltrombopag treatment.